UNC Joins Phase 3 CATT1 Trial Investigating Cadisegliatin as Adjunctive Therapy for Type 1 Diabetes
August 18, 2025
The University of North Carolina will serve as a study site for the vTv Therapeutics Inc. CATT1 Phase 3 trial investigating cadisegliatin as an adjunctive treatment to insulin in adults with type 1 diabetes (T1D). Cadisegliatin is a potential first-in-class, oral, liver-selective glucokinase activator for T1D that has been granted...